Artery Plaque Supplements: Evidence vs Hype
A clear-eyed, evidence-ranked look at which supplements have real data behind slowing or reversing arterial plaque, and which are mostly marketing, so you spend on what the trials actually support instead of guessing.
After a 2024 CT angiogram found soft plaque in his own arteries, Simon Hill reviewed the clinical-trial evidence on 8 commonly marketed supplements for atherosclerosis. His conclusion: only one has strong trial evidence, and even that is a prescription-strength dose, not a supplement-shelf product. The rest range from promising-but-unproven to actively contradicted.
Why it works▼
Discuss prescription-strength EPA (icosapent ethyl) with your physician if you have elevated triglycerides on a statin
EVAPORATE found a 9% reduction in total plaque volume vs an 11% increase on placebo; REDUCE-IT found a 25% reduction in major cardiac events. The one intervention here with imaging + outcomes support, but prescription-strength.
Consider standard-dose omega-3 (EPA/DHA) as general cardiovascular support
Broader omega-3 evidence supports general CV benefit even where plaque-imaging-specific proof is limited to the prescription dose.
Aged garlic extract is the best-supported true OTC option
Several imaging studies have looked at plaque/calcification with aged garlic extract, more than most options here, though still smaller and less consistent than the EPA trials.
Do not assume vitamin K2 lowers heart risk by directing calcium away from arteries
Hill calls this the calcification paradox: whether redirecting calcium lowers heart risk is unresolved; the mechanism story outruns the outcomes evidence.
Treat CoQ10, berberine, nattokinase and pomegranate extract as unproven for plaque reversal specifically
CoQ10 has a plausible mechanism but no plaque-imaging proof; nattokinase has one small positive and one null study (he addresses the viral Sinclair nattokinase claim); pomegranate has strong animal but weak human data; berberine's lipid pathway is real but untested against plaque imaging.
Do not use niacin as a plaque-reversal strategy based on HDL-raising alone
Niacin reliably raises HDL, but large outcomes trials found it did not reduce cardiac events: the clearest case of a supplement moving a biomarker without helping the patient.
Treat all of the above as additions to, never replacements for, the proven basics: lipid management, blood-pressure control, not smoking, and a whole-food diet
Hill's own framing: supplements can be useful additions but are never a replacement for the proven basics.
- People with known soft/non-calcified plaque wanting an evidence-first supplement decision
- Anyone tempted by nattokinase/CoQ10 hype who wants the real evidence picture
- Statin-hesitant people who need to see why proxy-marker wins (niacin/HDL) can still fail on outcomes
- This is educational, not a substitute for cardiology care. Discuss any supplement, especially prescription-strength EPA, with your physician, particularly if you take statins or blood thinners
- Do not self-prescribe icosapent ethyl; it is a prescription medication
- Nattokinase and other supplements with blood-thinning properties can interact with anticoagulants; disclose all supplements to your care team
- This protocol never claims any supplement cures or reverses heart disease outright; it reports what the trials show and do not show
- Educational only, not medical advice
- July 3, 2026 Protocol published.
New expert protocols and evidence updates, cited to the source. No spam; unsubscribe anytime.
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Independent curation. YourProtocol.ai is an independent platform. This protocol is based on the publicly available work of Simon Hill and is not created, reviewed, endorsed by, or affiliated with Simon Hill or The Proof · MSc Nutrition.